House dust mite

Type: Keyphrase
Name: House dust mite
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

Protect Your Baby Against Allergies - Try Animal Skin Bedding

For a baby, there can be no bettercomfort zone than it's mother's arms; so soft and tender.... no doubt that babiessleep so soundly in them! No matter how stressed you are, the sight of yourbaby's eyelids dropping to the swaying of your arms and then ... [Published MedIndia - Sep 12 2014]
First reported Jun 13 2014 - Updated Jun 13 2014 - 1 reports

Circassia Announces Results from Phase IIb Study

-- Circassia Announces Results from House Dust Mite Allergy Treatment Phase IIb Two-Year Follow-up Study --Oxford, UK - 13 June 2014: Circassia Pharmaceuticals plc ("Circassia" or "the Company") (LSE: CIR), a clinical-stage specialty biopharmaceutical ... [Published TrustNet - Jun 13 2014]
First reported Jun 10 2014 - Updated Jun 11 2014 - 1 reports

Allergy hospital admissions continue to soar

Medical Specialists™ Pharmacy discuss the rising number of hospital admissions relating to allergies and how the Western diet may be partially to blame. An increasing number of patients are requiring hospital treatment due to allergic reactions, and health ... [Published PRWeb - Jun 10 2014]
First reported Apr 25 2014 - Updated Apr 25 2014 - 1 reports

ALK enters collaboration to accelerate growth in China

Copenhagen, 2014-04-25 04:00 CEST (GLOBE NEWSWIRE) --ALK (ALK-B.CO / OMX: ALK B / AKABY / AKBLF) and China-based specialty pharmaceutical company Eddingpharm, today announced that they have agreed a collaboration that will expand ALK’s presence in China. ... [Published GlobeNewswire - Apr 25 2014]

Quotes

"Our findings have confirmed that it is crucial to study further the"
Steve Harris, Circassia's Chief Executive, said: "These encouraging trends suggest that our short-course house dust mite allergy treatment has lasting effects two years on with no further injections.  Results from long-term follow-up studies, even with smaller patient numbers, are invaluable for informing the design of future clinical studies across our portfolio of product candidates.  We believe our short-course SPIRE treatments could offer significant benefits and, having completed 18 clinical studies, our late-stage data set continues to underline our confidence in the ToleroMune® platform technology."

More Content

All (4) | News (4) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Protect Your Baby Against Allergies - Try Anima... [Published MedIndia - Sep 12 2014]
Circassia Announces Results from Phase IIb Study [Published TrustNet - Jun 13 2014]
Allergy hospital admissions continue to soar [Published PRWeb - Jun 10 2014]
ALK enters collaboration to accelerate growth i... [Published GlobeNewswire - Apr 25 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.